Suppr超能文献

神经激肽 1 受体在世界卫生组织 4 级星形细胞瘤、口腔鳞状细胞癌和尿路上皮癌中的免疫定位。

Immunolocalization of neurokinin 1 receptor in WHO grade 4 astrocytomas, oral squamous cell and urothelial carcinoma.

机构信息

Lahore Medical Research Center, LLP, Lahore, Pakistan.

Department of Pathology, Faculty of Medicine in Rabigh, King Abdulaziz University, Saudi Arabia.

出版信息

Folia Neuropathol. 2022;60(2):165-176. doi: 10.5114/fn.2022.116469.

Abstract

INTRODUCTION

Neurokinin-1 receptor (NK-1R) induces inflammatory reactions in peripheral tissues but its regulatory effects in target tissues is dependent on receptor signalling. Substance P (SP) has a high affinity for the NK-1R, to which it binds preferentially. We aimed to investigate the expression of NK-1R in World Health Organization (WHO) grade 4 astrocytomas as well as in oral squamous cell carcinoma (OSCC) and urothelial carcinoma, and its association with disease progression.

MATERIAL AND METHODS

The study included tissue samples from 19 brain astrocytomas, 40 OSCCs and 10 urothelial carcinomas. NK-1R expression was quantitatively assessed in the tumour cells using immunohistochemistry. The relationship between NK-1R expression in astrocytomas and recurrence-free interval has been explored.

RESULTS

The results showed that the NK-1R was intensely expressed in patients with WHO grade 4 astrocytoma, OSCC and urothelial carcinoma. However, cases clinically diagnosed as a low-grade cancer showed reduced NK-1R expression.

CONCLUSIONS

NK-1R is overexpressed in all cases of WHO grade 4 astrocytoma, OSCC and urothelial carcinoma. The ubi-quitous presence of SP/NK-1R complex during tumour development and progression suggests a possible therapeutic key strategy to use NK-1R antagonist as an adjuvant therapy in the future.

摘要

简介

神经激肽-1 受体(NK-1R)在周围组织中引起炎症反应,但它在靶组织中的调节作用取决于受体信号。P 物质(SP)与 NK-1R 具有高亲和力,优先与之结合。我们旨在研究世界卫生组织(WHO)4 级星形细胞瘤以及口腔鳞状细胞癌(OSCC)和尿路上皮癌中 NK-1R 的表达及其与疾病进展的关系。

材料和方法

本研究纳入了 19 例脑星形细胞瘤、40 例 OSCC 和 10 例尿路上皮癌的组织样本。使用免疫组织化学定量评估肿瘤细胞中的 NK-1R 表达。还探讨了星形细胞瘤中 NK-1R 表达与无复发生存期的关系。

结果

结果表明,NK-1R 在 WHO 4 级星形细胞瘤、OSCC 和尿路上皮癌患者中强烈表达。然而,临床上诊断为低级别癌症的病例显示 NK-1R 表达减少。

结论

NK-1R 在所有 WHO 4 级星形细胞瘤、OSCC 和尿路上皮癌病例中均过度表达。在肿瘤发生和进展过程中 SP/NK-1R 复合物的普遍存在表明,未来可能需要使用 NK-1R 拮抗剂作为辅助治疗的一种潜在治疗策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验